This biotechnology global forum, "Delivering Global Promise Through the Life Sciences" underlined how the latest social science research into genomics science can help inform key global economic and policy decisions.
As a follow up to the Outlook on Industrial Biotechnology Workshop organised in January 2010, a workshop entitled “Building an Efficient Bio-Based Economy through Industrial Biotechnology” was held in St Petersburg.
For many of today’s new biomedical innovations, the distinctions between different forms of medical products such as drugs, diagnostics and devices no longer apply. Biomedicine also tends to realize its potential today through process innovation, even more than product innovation.
This report is on how to support governments and industry in building a sustainable bio-based economy. The OECD Task Force on Industrial Biotechnology is considering the development of a set of recommendations in the area of Environmental and Economic Sustainability.
The main objectives of the panel were to launch the report from Montreal Workshop entitled “Towards the Development of OECD Best Practices for Assessing the Sustainability of Bio-based Products” and to communicate its main conclusions.
The key goal of the current work is to identify further means (e.g. international guidelines, policy recommendations) to implement the 2004 OECD Science and Technology Ministers mandate on “Biotechnology for Sustainable Growth and Development” .
This July 2009 symposium brought together the different communities – scientific, engineering, policy, public and legal – involved in synthetic biology and explored the opportunities and challenges posed by this emerging field.
Workshop discussions were structured around a set of issues papers – one for each of the sessions. The workshop was set up as a working roundtable discussion. 50 participants familiar with data sources for industrial biotechnology attended the workshop.
English, , 287kb
The aim of these guidelines is to propose a harmonised approach for the collection and analysis of biotechnology research and development (R&D) statistics in the government and higher education sectors.
This book reviews how the emergence of pharmacogenetics will impact the efficiency of pharmaceutical R&D and improve healthcare decision making and clinical care. It discusses what policies need to change in order for the public to reap the benefits from advances in diagnostic genetic testin